Zinganell, Anne
Göbel, Georg
Berek, Klaus
Hofer, Barbara
Asenbaum-Nan, Susanne
Barang, Matin
Böck, Klaus
Bsteh, Christian
Bsteh, Gabriel
Eger, Stephan
Eggers, Christian
Fertl, Elisabeth
Joldic, Damir
Khalil, Michael
Langenscheidt, Dieter
Komposch, Martina
Kornek, Barbara
Kraus, Jörg
Krendl, Reinhard
Rauschka, Helmut
Sellner, Johann
Auer, Michael
Hegen, Harald
Pauli, Franziska Di
Deisenhammer, Florian http://orcid.org/0000-0003-4541-8841
Funding for this research was provided by:
Sanofi
Article History
Received: 7 July 2023
Revised: 29 September 2023
Accepted: 30 September 2023
First Online: 19 October 2023
Declarations
:
: AZ has participated in meetings sponsored by, received speaking honoraria or travel funding from Biogen, Merck, Novartis, Sanofi-Genzyme and Teva. GG has nothing to disclose. KB has participated in meetings sponsored by and received travel funding from Roche and Biogen. BH has nothing to disclose. SA-N participated in meetings sponsored by and received travel grants from Biogen, Genzyme-Sanofi, Janssen, Merck, Novartis Pharma, Pfizer, Roche and Teva. MB participated in meetings sponsored by and received travel grants from Novartis, Janssen, Celgene and Shire. TB has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, Celgene/BMS, GSK, GW/Jazz Pharma, Horizon, Janssen-Cilag, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, and Teva. His institution has received financial support in the past 12 months by unrestricted research grants (Bayer, Biogen, Celgene/BMS, Merck, Novartis, Sanofi Aventis, and Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Celgene/BMS, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, and Teva. KB has nothing to disclose. CB has participated in meetings sponsored by or received travel funding by: Celgene, Janssen/Johnson Johnson, Lilly, Merck, Novartis, Roche, and Sanofi/Genzyme. GB has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene-BMS, Lilly, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. SE has nothing to disclose. CE received honoraria for participation in advisory boards from Biogen, Genzyme-Sanofi, Gilead, Merck, Novartis, Roche, and Teva Ratiopharm; speakers honoraria from Merck, Genzyme-Sanofi, Teva Ratiopharm, Roche, Biogen, Novartis; and honoraria for conducting clinical GCP trials from Merck, Teva Ratiopharm, Roche, and Genzyme-Sanofi. EF has received honoraria for presentations or consulting from Almirall, BMS, Biogen, Böhringer, Janssen, Merck, Novartis and Roche. DJ has participated in meetings sponsored by, received speaking honoraria or travel funding from Almirall, Biogen, Merck, Novartis, Sanofi and Roche. MK has received funding for travel and speaker honoraria from Bayer, Novartis, Merck, Biogen Idec and Teva Pharmaceutical Industries Ltd. and serves on scientific advisory boards for Biogen Idec, Merck Serono, Roche, Novartis and Gilead. DL has received honoraria from Biogen, Novartis, Merck, and Roche. MK has participated in meetings sponsored by or travel funding from Novartis, Roche, Biogen, Merck, Sanofi-Genzyme and Teva. BK has received honoraria for speaking and/or consulting from Biogen, BMS Celgene, Johnson&Johnson, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. JK has received honoraria for speaking and/or consulting from Abbvie, Almirall, Biogen, BMS Celgene, Cannaxan, Grünenthal, Johnson&Johnson, Lilly, Merck, Novartis, Pharmgenetix, Roche, Sandoz, Sanofi-Genzyme, and Teva. RK has nothing to disclose. HR has participated in meetings sponsored by, or received honoraria for acting as an advisor/speaker from Alexion, Biogen, Genzyme-Sanofi, Merck and Novartis. JS received honoraria for presentations from Alexion, Angelini, BMS, Biogen, Boehringer, Janssen, Novartis, Roche, Pfizer, Roche, Sandoz and Sanofi. He serves on scientific advisory boards of Alexion, BMS, Biogen, Boehringer, Novartis, Roche, Sandoz and Sanofi. He is a medical monitor for a clinical trial of Immunic. MA received speaker honoraria and/or travel grants from Biogen, Merck, Novartis and Sanofi. HH has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Biogen, Celgene, Novartis and Teva. FDP has participated in meetings sponsored by, received honoraria (lectures, advisory boards, and consultations) or travel funding from Bayer, Biogen, Janssen-Cilag, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene and Roche. Her institution has received research grants from Roche. FD has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, Biogen, Celgene, Genzyme-Sanofi, Janssen, Merck, Novartis Pharma, and Roche. His institution has received research grants from Biogen and Genzyme-Sanofi. He is the section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders) and review editor of Frontiers in Neurology.
: The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Medical University of Innsbruck (1160/2017). As this was a retrospective study, the ethics committee did not require written informed consent from study participants.